The prevalence of ER-low-positive breast cancer and its relation to tumor characteristics in Syria

[1] Martei, Y.M., et al., Breast cancer in low-and middle-income countries: why we need pathology capability to solve this challenge. Clinics in laboratory medicine, 2018. 38(1): p. 161–173. MarteiY.M. Breast cancer in low-and middle-income countries: why we need pathology capability to solve this challenge Clinics in laboratory medicine 2018 38 1 161 173 Search in Google Scholar

[2] Arnold, M., et al., Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 2022. 66: p. 15–23. ArnoldM. Current and future burden of breast cancer: Global statistics for 2020 and 2040 The Breast 2022 66 15 23 Search in Google Scholar

[3] Lou, M.W., et al., Linking physical activity to breast cancer via inflammation, Part 2: The effect of inflammation on breast cancer risk. Cancer Epidemiology, Biomarkersa & Prevention, 2023. 32(5): p. 597–605. LouM.W. Linking physical activity to breast cancer via inflammation, Part 2: The effect of inflammation on breast cancer risk Cancer Epidemiology, Biomarkersa & Prevention 2023 32 5 597 605 Search in Google Scholar

[4] Jayashree, V. and M. Velraj, Breast Cancer and various Prognostic Biomarkers for the diagnosis of the disease: A Review. Research Journal of Pharmacy and Technology, 2017. 10(9): p. 3211–3216. JayashreeV. VelrajM. Breast Cancer and various Prognostic Biomarkers for the diagnosis of the disease: A Review Research Journal of Pharmacy and Technology 2017 10 9 3211 3216 Search in Google Scholar

[5] Asaad, R.A. and S.S. Abdullah, Breast cancer subtypes (BCSs) classification according to hormone receptor status: Identification of patients at high risk in Jableh-Syria. Research Journal of Pharmacy and Technology, 2018. 11(8): p. 3703–3710. AsaadR.A. AbdullahS.S. Breast cancer subtypes (BCSs) classification according to hormone receptor status: Identification of patients at high risk in Jableh-Syria Research Journal of Pharmacy and Technology 2018 11 8 3703 3710 Search in Google Scholar

[6] Luo, C., et al., Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer. The Breast, 2022. 63: p. 24–28. LuoC. Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer The Breast 2022 63 24 28 Search in Google Scholar

[7] Guo, Y.-Z., et al., Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pacific Journal of Cancer Prevention, 2013. 14(1): p. 243–248. GuoY.-Z. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies Asian Pacific Journal of Cancer Prevention 2013 14 1 243 248 Search in Google Scholar

[8] Asaad, R.A., Hormone receptor status and its relation to C-reactive protein and other prognostic factors in breast cancer in Jableh-Syria. Research Journal of Pharmacy and Technology, 2017. 10(9): p. 3003–3010. AsaadR.A. Hormone receptor status and its relation to C-reactive protein and other prognostic factors in breast cancer in Jableh-Syria Research Journal of Pharmacy and Technology 2017 10 9 3003 3010 Search in Google Scholar

[9] Allison, K.H., et al., Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. 2020. AllisonK.H. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update 2020 Search in Google Scholar

[10] Kadi, M.S., et al., Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center. Cureus, 2023. 15(7). KadiM.S. Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center Cureus 2023 15 7 Search in Google Scholar

[11] Aleskandarany, M.A., et al., Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology, 2018. 85(1–2): p. 23–34. AleskandaranyM.A. Tumour heterogeneity of breast cancer: from morphology to personalised medicine Pathobiology 2018 85 1–2 23 34 Search in Google Scholar

[12] Makhlouf, S., et al., The clinical and biological significance of estrogen receptor-low positive breast cancer. Modern Pathology, 2023. 36(10): p. 100284. MakhloufS. The clinical and biological significance of estrogen receptor-low positive breast cancer Modern Pathology 2023 36 10 100284 Search in Google Scholar

[13] Asaad, R.A., Lymph Node Ratio (LNR) as a predictive factor in addition to pNstaging in Syrian-breast cancer patients at diagnosis. Research Journal of Pharmacy and Technology, 2018. 11(3): p. 933–940. AsaadR.A. Lymph Node Ratio (LNR) as a predictive factor in addition to pNstaging in Syrian-breast cancer patients at diagnosis Research Journal of Pharmacy and Technology 2018 11 3 933 940 Search in Google Scholar

[14] Łukasiewicz, S., et al., Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 2021. 13(17): p. 4287. ŁukasiewiczS. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review Cancers 2021 13 17 4287 Search in Google Scholar

[15] Puhalla, S., S. Bhattacharya, and N.E. Davidson, Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol, 2012. 6(2): p. 222–36. PuhallaS. BhattacharyaS. DavidsonN.E. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care Mol Oncol 2012 6 2 222 36 Search in Google Scholar

[16] Reinert, T., et al., Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Frontiers in Endocrinology, 2022. 13: p. 1015388. ReinertT. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer Frontiers in Endocrinology 2022 13 1015388 Search in Google Scholar

[17] Moldoveanu, D., et al., Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1–10%) Breast Cancer. Annals of surgical oncology, 2023. 30(11): p. 6475–6483. MoldoveanuD. Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1–10%) Breast Cancer Annals of surgical oncology 2023 30 11 6475 6483 Search in Google Scholar

[18] Paakkola, N.-M., et al., The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. ESMO open, 2021. 6(6): p. 100289. PaakkolaN.-M. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis ESMO open 2021 6 6 100289 Search in Google Scholar